This interview will appear in the January 2024 issue of Evidence-Based Oncology.™ Each year, our January issue features a recap of proceedings from the American Society of Hematology Meeting and Exposition.
Standard Lithium Ltd. (CVE:SLL – Get Free Report) shares rose 16.4% during mid-day trading on Wednesday . The company traded as high as C$6.95 and last traded at C$6.95. Approximately 1,408,977 shares were traded during trading, an increase of 298% from the average daily volume of 354,366 shares. The stock had previously closed at C$5.97. […]
Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).
Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.